More than half of Americans qualify for GLP-1 receptor agonist drugs, but many can't afford them. Experts share cheaper ...

With sales of around $2.7 billion in 2015, Victoza has dominated the GLP-1 market despite competition from AstraZeneca. But Lyxumia’s sales in 2015 were miniscule in comparison, at $38 million ...

Ozempic maker Novo Nordisk says it has developed a compound that’s shown to be a one-two punch for appetite suppression and ...

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people ... Liraglutide is on the market as Victoza for diabetes and Saxenda for obesity.

For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.

Participants in Wegovy clinical trials were more likely to report “severe gastrointestinal adverse reactions,” the FDA's ...

GLP-1 (glucagon-like peptide-1 ... Semaglutide (Ozempic, Wegovy); Liraglutide (Victoza, Saxenda); and Dulaglutide (Trulicity). While the majority of U.S. employers are covering these drugs ...

Research has found that while treatments such as liraglutide (Victoza) and tirzepatide may result in expected muscle loss in line with weight reduction, they can also improve muscle quality. However, ...

After losing and regaining the same 20-plus pounds more times than she could count, Anita Blanchard concluded that diets ...